NCT07082725: A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)

Study type: INTERVENTIONAL. Phase: PHASE3.

Publisher

ClinicalTrials.gov

USA

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

At a glance

Publisher: ClinicalTrials.gov
Region: USA
Scope: Research
Published: July 14, 2026
Language: EN

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Summary excerpt

Study type: INTERVENTIONAL. Phase: PHASE3.

Source route

Continue on clinicaltrials.gov

Leave the platform to read the original full article on the publisher site.

Source: ClinicalTrials.gov

Scope: Research

Open original article

Related coverage

More related coverage

NIHR School for Public Health Research/6h ago

NIHR SPHR fellowships in public health research 2026

University of British Columbia/5h ago

The U.S. just approved a giant space mirror to test ‘sunlight on demand.’ Low Earth orbit is getting weird

UNLP Health Sciences/5h ago

Vacaciones de Invierno en la Biblioteca Pública

UNLP Health Sciences/5h ago

Vacaciones de Invierno en el Teatro UNLP

NCT07082725: A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC) | Pharma Surge